



Growth Strategy for Medical Systems Business

Shimadzu Corporation

Kunimasa Ito, Senior Managing Executive Officer and Medical Systems Division General Manager

Diagnostic X-Ray System Market Share (2015, excluding CCD, CR, retrofits, etc.)



Source: IHS Market Report

Philips

24.9%

SHIMADZU

Current Status of Business

Overview of Diagnostic Imaging Equipment Market

Global market for diagnostic imaging equipment is about 3 trillion ven with strong growth.

- > Of that, global market size for diagnostic X-ray systems is about 700 billion ven.
 - ♦ Globally, Shimadzu is the fourth largest (7.2 %), after the three major non-Japanese manufacturers.

2015

2016

- Increasing number of companies have entered the radiography system market (general radiography systems and mobile X-ray systems). Intense price competition and commoditization
- ◆ The most important regions are the United States, China, and Japan, which have large domestic markets.

Diagnostic X-Ray System Market by Region





2017

2018

2019

2020

GE

13.6%





Shimadzu

7.2%



Current Status of Business Medical Systems Business Results

• Improving growth potential and reforming profit structure

- Consolidated net sales grew by 10.8 billion yen in five years (+20 % at 3.6 % CAGR). In addition to strengthening the base of key businesses (X-ray businesses), also establish businesses in new areas.
- Consolidated operating income grew by 0.8 billion yen during the same time (+41 % at 7.2 % CAGR)



Shimadzu Medical Systems Business Results

BRIMADZU Product Line and Direction for Increasing Competitiveness

Improving Procedure Support Functionality Expanding/Improving Diagnostic Capabilities Diagnostic X-Ray Systems General Radiography Mobile C-arm Mobile X-Ray Fluoroscopy Angiography System System System System System Fluoroscopy/Video Recording Functions Medical Service Efficiency Advanced Diagnostic Solutions New Procedure Support Solutions Improvement Solutions Electronic Automatic Returning **Dedicated Breast** Near-Infrared Radiation Therapy Fluorescence Medical Records Patient Reception PET System Imaging System Imaging System System and Payment System System

4

April 12, 2019

Medium-Term Management Plan Overview of Medium-Term Management Plan

Achieving Sustained Growth and Improved Profitability by Strengthening Angiography System, North America, and Aftermarket Businesses

Performance Targets for Year Ending March 2020

Consolidated Sales

Consolidated Operating Income

71.0 billion yen

(10 % increase from year ending March 2017)

4.0 billion yen

(135 % increase from year ending March 2017)

Angiography System Business

Target sales for year ending March 2020: 57 % increase from year ending March 2017

North America Business

Target sales for year ending March 2020: 26 % increase from year ending March 2017

Aftermarket Business

Target sales for year ending March 2020: 9 % increase from year ending March 2017

Medium-Term Management Plan Strengthening the North America Business

• Achieve the next growth by strengthening business capabilities and releasing new products.

Target sales for year ending March 2020: +26 % increase from year ending March 2017

- Special demand for digital X-ray systems that continued since 2017 will return to normal from the second half.
- Acquire Core Medical Imaging Inc. in the U.S. and transition to direct sales to strengthen profitability.
- Expand sales of diagnostic X-ray systems.
 - Increase usage rate of SONIALVISION G4 examination room.
 - Completed transition smoothly to new mobile systems.
 - Promote sales of radiography systems in clinic market.
- Expand sales of angiography systems.
 - Strengthen sales capabilities and prepare service capabilities.
 - Establish installation records for cardiovascular and lower extremity interventional applications.
- Strengthen support for customers in the East.
 Establish East Parts Center and Training Center.



Locations in

North America

Medium-Term Management Plan Strengthening the North America Business

- Release new products, especially Radiography/Fluoroscopy products
 - FLUOROspeed X1 (2nd half of FY 2019)

Offer an ultimate multipurpose X-ray examination room

- High quality digital system equipped with FPD and state-of-the-art radiation dose reduction functionality
- Table-side operability demanded in the U.S.
- Also include features for examining elderly and obese patients, in addition to regular examinations



New FLUOROspeed X1

SONIALVISION G4 (1st half of FY 2019)

Strengthen digital radiography functionality and include chest exam capability

RADspeed Pro with dynamic image analysis capability (Feb. 2019)

General radiography system with new diagnostic functionality

Lung function visualization, breathing function assessment, and postoperative follow-up observation

Evaluation about Shimadzu Medical Business in U.S.

Shimadzu Received #1 Customer Experience from IMV*

Benchmarking for 2019 The Diagnostic Imaging Equipment Customer Experience in the U.S.



Research about customer experience of pre/post-purchase support, product integrity and overall product satisfaction, only Shimadzu received high rankings (\star) at all customer touchpoints out of twelve manufacturers

High Performance on Multiple Touchpoints Contributes to the Best Customer Experience Scores

	Customer Experience Score Ranking	Equipment Awareness	Equipment Knowledge	Equipment Selection	Equipment Integrity	Service Provided	Manufacturer Support	Satisfaction & Loyalty	
Shimadzu	1	*	*	*	*	*	*	*]
	Fluoros	scopy			Radiograp	hy	Mobile X-ra	Remarks* : established a leader in research fo medical ima clinical diag instruments https://imvin	: IMV was d in 1977, markets or the aging and gnostic s markets nfo.com

🕀 SHIMADZU

Medium-Term Management Plan Strengthening the Angiography System Business

Target sales for year ending March 2020: +57 % increase from year ending March 2017

 Expand market for minimally invasive catheterization procedures Increasing consolidation of high-end diagnostic equipment Expansion trend in markets for urgent-care angiography systems outside Japan

New product release

Trinias unity smart edition (April 2018)

Expand/improve product line and provide multipurpose clinical applications

SCORE Chase lower extremity interventional support

software (October 2018)

 Automate treatment support starting with examination of lower extremities









Shimadzu Serial Exposure Control Technology Using Digital General Radiography for Dynamic Chest Diagnostics

- From static to dynamic diagnostic imaging DR "NEUTRAL" 2.0 supports a wide range of clinical applications
 - Shimadzu X-ray technology + Konica Minolta FPD/dynamic image data analysis
 - Serial exposure technology with low dose X-ray pulses at 15 fps (exposure dose is equivalent to IAEA guidance values for static frontal + lateral radiography)
 - Enables dynamic image examinations in general radiography rooms

Anticipated clinical applications

- Visualization of lung function
- Assessment of breathing function (COPD*, etc.)
- Follow-up observation of chest area after surgery





DR "NEUTRAL" 2.0

* COPD (chronic obstructive pulmonary disease) is a general term for chronic bronchitis and emphysema. In Japan, there are an estimated about 5.3 million COPD patients, or 8.6 % of the population over 40 years old (Source: Japanese Respiratory Society website)

Shimadzu X-Ray Video Control Technology Bone Diagnostics for "Super-Aging" Society

- Increases usage rate of examination rooms Supports bone density measurements using SONIALVISION G4 fluoroscopy system
 - New first-in-Japan osteoporosis examination system serves three roles:
 (1) Bone density exam, (2) Plain radiography, (3) Tomosynthesis radiography
 - Al used: SmartBMD AI Assist automatically detects femur measurement area (1st half 2019)
 Improves work efficiency at healthcare providers



() SHIMADZU

SmartBMD Bone Density Measurement (released to Japanese market only)



						8011:2	014/10/	
5.0.1	NRC 7	u	WEI 04.4					
10.01	un			生年月日 1950/05/10				
				_				
					170			
					140			
あなたの機構	7月密度	11.121[9](cm²]℃す.		1.10			
1000111927	22 -1.	58 % 77	r.		100			
					178			
1048045	REC BLA	02122.5	19609.		100		312	
若年成人とお	親すると	94.04 %	C. 1.	0.0072				
					1.00			
					1.00			
(11288)>					1.00			
正常	若午成	人平均值的	80%6X上		1.00	1x		
OTHER !!	石中成	人生的価の	70%以上~80%素		114			
on state of	-	a manda av	No. 4 in		1.00			
THEFT	G+8L	CT-1200	-V754-85		····	5.6.5	ATE	
제24/7년	100	8992	項巴兹(EMD)	MALER	RUBBLER	Semicist	1,022	
20149 209 20	64.0	1244	1.13Mairmil	1.30 %	124.45 %	05.55.16	-0.36	
	10	10	(0.000) (0.000)	1932240			4.94	
NETRO		1.1	1.156(g/cm²]	+0.96 %		-		
期夏年月日 2014/10/10	64.4		a a still a loss 12			-		
8034/06/06 8034/10/10 2034/06/06	64.4 64.0	L1	1.149(0011)					
80140606 8034/10/10 2034/06/06 2034/10/10	64.4 64.0 64.4	L1 L2	1.109(g/cm²)	-4.97 %				
期日中月日 2014/10/10 2014/10/10 2014/06/06 2014/06/06	64.4 64.0 64.4 64.0	12	1.109(g/cm ²) 1.167(g/cm ²)	-4.97 %		1		
HE/F/HI 2014/10/10 2014/10/10 2014/10/10 2014/06/05 2014/10/10	64.4 64.0 64.0 64.1 64.0		1.100[g/cm ²] 1.167[g/cm ²] 1.147[g/cm ²] 1.147[g/cm ²]	-4.97 %		i		
HE/F/HI 2014/10/10 2014/10/10 2014/10/10 2014/10/10 2014/10/10 2014/10/10 2014/10/10	64.4 64.0 64.4 64.0 64.4 64.0 64.4 64.0		1.10(p(m ²) 1.10(p(m ²) 1.16(p(m ²) 1.16(p(m ²) 1.160(p(m ²))	-4.37 %				





Measurement area selection process automated by AI 11

Medium-Term Management Plan

Strengthening the Aftermarket Business

Service businesses

Target sales for year ending March 2020: +9 % increase from year ending March 2017

> Utilize customer support centers

Strengthen support for users of diagnostic/treatment support systems

- Offer 24-hour on-site service and periodic inspections on holidays and closed days
- Deploy in China (scheduled to open in January 2020)
- Utilize Global Parts Center (Singapore)
 - Expand/improve capabilities for supplying parts from Asia region.
- Expand service coverage area (U.S.: January 2019)
 - Strengthen direct service capabilities, expand sales, and increase profitability
- Use IoT to collect information for predicting failures
 - Remote troubleshooting/repair and interactive remote maintenance services
 - Analyze data, accumulate experience, and deploy outside Japan.

Call center available 24-hours a day, 365 days a year

The center can be called anytime, 24hours a day, 365 days a year, and even at night or during holidays.

Calls answered directly by expert engineers

The call center is staffed by engineers with extensive field experience and specialized skills. That means they can directly troubleshoot problems or provide operating instructions quickly and accurately.

24-hour instrument monitoring



Achieving Additional Growth

Increase/Strengthen Production Capacity and Reduce Costs

- New building completed at manufacturing subsidiary Shimane Shimadzu Corp. Investment: 1.74 billion yen; Completion: February 2019
- Main plant for manufacturing diagnostic X-ray systems
- Expand production capacity by 50 % (by 2025).
 - Uses IoT to automate conveying and improve production efficiency
 - Increased/improved machining equipment
- Established design prototyping center
 Evaluate prototypes quickly and reduce costs
- Centralize product distribution.

Shimane Shimadzu Corporation (Izumo City, Shimane)

New building

Achieving Additional Growth Progress Establishing Track Record for Radiation Therapy Systems

- Promote the widespread use of high precision cancer treatments with SyncTraX series tumor-tracking systems for radiotherapy
 - > 15 systems delivered in Japan (as of end of March 2019)
 - Two-directional X-ray fluoroscopy system with FPD + 3-dimensional dynamic position detection technology
 - Irradiated with radiotherapy beam only when tumor with movement enters planned treatment area
 - Smart Aligner static positioning function (optional)
 - Target areas: lungs, liver, prostate cancer (stereotactic body), head and neck tumor (stereotactic head)





Example of delivered system (Uonuma Kikan Hospital)



Smart Aligner static positioning function

() SHIMADZU **Achieving Additional Growth** Increasing Awareness of Dedicated Breast PET (DB-PET) in Japan and Deploying DB-PET outside Japan

- Progress in Japan
 - > 2018 Clinical Practice Guidelines for Systemic Treatment of Breast Cancer (issued by Japanese Breast Cancer Society) was revised to affirm using DB-PET for opportunistic breast cancer screening.
 - > The cancer detection rate for breast cancer screening by breast PET is about 1.0 %, which is high.
 - Health management: To increase breast cancer screening rate, the entire cost of breast PET screening is covered for employees.
- Deploying DB-PET outside Japan
 - Currently in product registration application process for planned release in China



Example of DB-PET

R



Recurrence discovered during screening after reconstructive breast surgery (mammography not usable and ultrasound 15 showed no abnormalities)

🕀 SHIMADZU

Achieving Additional Growth - Support for Working Practice Reforms at Healthcare Institutions Streamlining Patient Processing at Healthcare Institutions, from Reception to Payment

- Sales and service started cooperatively by Shimadzu Group companies
- For hospitals

Extensive product line and total support for outpatient processing

- Returning patient reception system
- Examination/payment display system
- Treatment fee payment system
- For clinics
 - Countertop payment system that can link payments to electronic medical records



Smooth and Reliable Processing within Hospitals



SHIMADZU Achieving Additional Growth Providing Surgical Support with Near Infrared Light Technology and Deploying Technology outside Japan



Award Received from Frost & Sullivan in the U.S.

2018 APAC Fluorescence Surgical Imaging for Breast Cancer New Product Innovation Award

LIGHTVISION was recognized for having a major impact on healthcare practices and offering a significant potential for shortening surgery times in the future, with applicability for a broad range of surgical procedures, by offering surgeons technology that can be used to observe areas of interest in detail with a LIGHTVISION near-infrared fluorescence imaging system.





Identify sentinel lymph nodes during breast cancer surgery

Assess blood flow through flaps during reconstructive breast surgery

Assess vascular patency during coronary bypass surgery

Assess blood flow through the gastrointestinal tract

Identify sentinel lymph nodes for malignant melanoma

Expanding Range of Clinical Applications



Identifying sentinel lymph nodes for breast cancer



Reconstructive breast surgery



Blood flow in gastrointestinal tract



Coronary bypass surgery



Identifying sentinel lymph nodes for malignant melanoma

Advanced Healthcare Measures

Catheterization procedures based on localized blood sampling

Examination and treatment of high blood pressure due to primary aldosteronism

- Identify and treat region with excessive secretion, shorten procedure time, and achieve same-day outpatient procedure status in future
- Start sales for research applications (April 2019)

Establish method for early detection of Alzheimer's from blood

Estimate amyloid plaque levels in the brain from a tiny quantity of blood plasma Started amyloid MS contract analysis service (August 2018)

Support research on new cancer treatment methods - cancer photoimmunotherapy

Provided research support and treatment area observation for cancer photoimmunotherapy (NIR-PIT)

Colon cancer screening

Conducted validation study for health screening users (October 2018)

Healthcare R&D Center

Promote healthcare product development based on integrating analytical instrument and medical system technologies Promoted open innovation (center completed February 2019)





Blood Test (minimally invasive, inexpensive, and suitable for largescale examinations) Blood Mass spectrometry 0.6 mL Check for presence of beta-amyloids





18

SHIMADZU Excellence in Science

Contributing to Society through Science and Technology Realizing Our Wishes for the Well-being of both Mankind and the Earth

✤ Future result values indicated in this presentation document are projections of the future based on information available at the time the document was released and include potential risks and uncertainties. Consequently, due to a wide variety of factors, actual results may differ significantly from the projections indicated in this document.

Shimadzu Corporation